Vimeo logo Twitter logo LinkedIn logo

Newsletters

npif stripes
Chris Yates & Chris Hand from Abingdon Health with Mark Wilcockson from the British Business Bank

Abingdon Health  has successfully raised £22million following its admission to the AIM market of the London Stock Exchange.

Abingdon is a lateral flow diagnostics company providing contract service solutions to a global client base in the healthcare sector and other industries. Services offered by the Company to its clients including product development, regulatory support, technology transfer and commercial manufacturing. The Company has developed and is manufacturing the AbC-19TM Rapid Test, an antibody test for COVID-19 indicating whether a person is generating IgG antibodies to the spike protein of the SARS-CoV-2 virus. The Company is also working with other customers to transfer their COVID-19 antigen tests to manufacture, and is manufacturing a component of a rapid PCR (polymerase chain reaction) test.  The Company also produces lateral flow tests covering non-COVID-19 applications in areas such as self-test HIV, equine infection, human fertility, blood cancer and other infectious diseases across the healthcare sector as well as other areas such as fuel contamination in the aviation sector and testing for water contaminants.

Abingdon Health was first backed by NPIF – Mercia Equity Finance, which is managed by Mercia and part of the Northern Powerhouse Investment Fund in 2019 and has received investment of £2.1milion from NPIF alongside other investors which was used to develop the company’s propriety technology, fund the acquisition of a new lateral flow manufacturing facility, help expand the senior leadership team and develop the Board through the appointment of several high profile non-executive directors.

Chris Yates, CEO of Abingdon Health said: “We are pleased to have achieved this important milestone and to be making our debut on the AIM market of the London Stock Exchange today.  The money raised will, amongst other things, enable us to scale up our manufacturing in order to meet the demand for our AbC-19TM rapid lateral-flow test and allow us to further establish our global commercial and operational footprint in broader areas including infectious disease, fertility, cancer markers, animal health, plant pathogen and environmental testing.  I would like to thank Mercia and NPIF for their support and we are looking forward to this next exciting chapter in Abingdon Heath’s development.”

Mark Wyatt, Investment Director for Mercia said: “Abingdon is a good example of the sort of business that NPIF is looking to support.  It is great to see Abingdon showcasing the strong research and development and manufacturing capabilities available in the North of England.  The business is creating high-value life science jobs off the back of delivering products of significant relevance to multiple different markets, including human and animal health and other industrial sectors. It has been a pleasure working with the experienced team and seeing them delivering on a very focused and ambitious business proposition. We are delighted that the future potential of the company is being supported by the wider investment community and we look forward to watching Abingdon flourish during its next phase of growth.”

Ken Cooper, MD of the British Business Bank said “With £500m of funding to back ambitious companies across the North, NPIF is committed to supporting companies like Abingdon Health on their growth journey. This is an excellent example of an NPIF investee business growing in value, while driving innovation and employment opportunities in the region. The company’s AIM listing is a vote of confidence in its future growth plans and we wish Chris and the team every success in the future.”

The Northern Powerhouse Investment Fund project is supported financially by the European Union using funding from the European Regional Development Fund (“ERDF”) as part of the European Structural and Investment Funds Growth Programme 2014-2020 and the European Investment Bank.

Digital wellbeing company set for healthy future with NPIF backing

Joe Gaunt, hero
Joe Gaunt, CEO of Hero Wellbeing

Leeds-based health-tech platform hero has raised £825,000 investment from NPIF – Mercia Equity Finance, which is managed by Mercia and part of the Northern Powerhouse Investment Fund, to support its continued growth.

With the support of NPIF funding, this will allow hero to further enhance its software platform and develop its marketing strategy. The company helps organisations to deliver tailored health and wellbeing programs and offers services ranging from coaching and training to medical screening and health and nutrition advice. What makes hero unique is its Navigator platform, which can track the impact of different wellbeing activities on individuals and overall business performance, whilst also measuring the return on investment.

hero was launched in April 2018 by Joe Gaunt, the former UK Managing Director of workspace provider WeWork and winner of the regional Great British Entrepreneur Awards 2020. It now employs more than 50 team members  and serves over 100 clients including Vodafone, the NHS, Arsenal FC and Legal & General. It has also won contracts from real estate operators such as Moda Living who are offering it to residents. The company currently employs over 50 staff and the funding will allow it to create six new jobs.

Joe Gaunt, CEO of Hero Wellbeing, said: “We have enjoyed a successful two years since our launch in 2018 but this funding will allow us to further enhance our products, accelerate growth and continue to build out our team.”

Mark Wilcockson, Senior Manager at British Business Bank, said: “NPIF continues to support high-growth businesses in the North, providing vital funding to enable job creation and expansion into new markets. This investment into hero, a forward thinking business with an important purpose, demonstrates how this funding can make a real and measurable difference to businesses across the Northern Powerhouse region, in turn helping to create a more prosperous regional economy.”

Megan Noble of Mercia said: “There has been growing recognition amongst businesses of the importance of employee health and wellbeing and the pandemic has brought this into even sharper focus. Hero’s approach allows employers’ to measure the effectiveness of such schemes.”

The Northern Powerhouse Investment Fund project is supported financially by the European Union using funding from the European Regional Development Fund (ERDF) as part of the European Structural and Investment Funds Growth Programme 2014-2020 and the European Investment Bank.

Enterprise Ventures Limited is authorised and regulated by the Financial Conduct Authority (FRN: 183363).  EV Business Loans Limited is authorised and regulated by the Financial Conduct Authority (FRN: 443560).

Editors Notes

NPIF Newsletters

For the latest news and views join our mailing list

Join our mailing list

Subscribe to receive our newsletters, updates, information and invites to events, relating to our products and services



By submitting your details via this form, you agree to our use of your data as per our Privacy Notice

Follow npifbbb

Latest News

Sean Hutchinson, Senior Investment Manager at the British Business Bank
Business Matters: Role of NPIF in supporting innovation-led businesses

Sean Hutchinson, senior investment manager at the British Business Bank, discusses key findings from the latest Backing ...

Signpost microfinance icon

Microfinance

£25k – £100k

Microfinance page
Learn More
Debt finance icon of a road map

Debt Finance

£100k – £750k

Debt Finance page
Learn More
equity finance icon

Equity Finance

£50k – £2m

Equity Finance page
Learn More

For the latest news and views join our mailing list

Join our mailing list

Subscribe to receive our newsletters, updates, information and invites to events, relating to our products and services



By submitting your details via this form, you agree to our use of your data as per our Privacy Notice